Berkeley Lights

OverviewSuggest Edit

Berkeley Lights provides technology solution for single cell manipulation for biopharma, diagnostics, and life science research. It specializes in cell line development, antibody discovery, gene discovery, and cell therapies.

TypePublic
Founded2011
HQEmeryville, CA, US
Websiteberkeleylights.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Aug 2020)208(+2%)
Job Openings57
Revenue (FY, 2019)$56.7 M(+82%)
Cybersecurity ratingBMore

Key People/Management at Berkeley Lights

Andy Last

Andy Last

Chief Commercial Officer
Kevin Chapman

Kevin Chapman

Chief Scientific Officer
Keith Breinlinger

Keith Breinlinger

Chief Technology Officer
Andrew McFarland

Andrew McFarland

SVP, Research and Development
Stuart Merkadeau

Stuart Merkadeau

General Counsel
Mark Lasinski

Mark Lasinski

SVP, Global Sales
Show more

Berkeley Lights Office Locations

Berkeley Lights has an office in Emeryville
Emeryville, CA, US (HQ)
5858 Horton St #320
Show all (2)

Berkeley Lights Financials and Metrics

Berkeley Lights Revenue

Embed Graph
View revenue for all periods
Berkeley Lights's revenue was reported to be $56.69 m in FY, 2019 which is a 81.1% increase from the previous period.
USD

Revenue (Q1, 2020)

13.8m

Gross profit (Q1, 2020)

10.0m

Gross profit margin (Q1, 2020), %

72.4%

Net income (Q1, 2020)

(8.4m)

EBIT (Q1, 2020)

(8.2m)

Cash (31-Mar-2020)

70.3m
Annual
USDFY, 2018FY, 2019

Revenue

31.3m56.7m

Revenue growth, %

81%

Cost of goods sold

8.2m13.2m

Gross profit

23.1m43.5m
Quarterly
USDQ1, 2019Q1, 2020

Revenue

12.6m13.8m

Cost of goods sold

2.8k3.8m

Gross profit

9.8k10.0m

Gross profit Margin, %

0%72%
Annual
USDFY, 2018FY, 2019

Cash

99.6m81.0m

Accounts Receivable

11.7m9.3m

Prepaid Expenses

4.8m7.8m

Inventories

2.9m7.2m
Quarterly
USDQ1, 2020

Cash

70.3m

Accounts Receivable

10.0m

Prepaid Expenses

7.2m

Inventories

10.7m
Annual
USDFY, 2018FY, 2019

Net Income

(23.3m)(18.3m)

Depreciation and Amortization

4.2m4.8m

Inventories

212.0k(4.0m)

Accounts Payable

1.1m494.0k
Quarterly
USDQ1, 2019Q1, 2020

Net Income

(4.2m)(8.4m)

Depreciation and Amortization

1.2m1.3m

Inventories

(649.0k)(3.5m)

Accounts Payable

148.0k1.2m
USDFY, 2018

Debt/Equity

0.2 x

Debt/Assets

0.1 x

Financial Leverage

1.4 x
Show all financial metrics

Berkeley Lights Revenue Breakdown

Embed Graph

Berkeley Lights revenue breakdown by business segment: 87.2% from Antibody Therapeutics, 8.3% from Synthetic Biology and 4.5% from Other

Berkeley Lights revenue breakdown by geographic segment: 52.7% from North America, 25.5% from Asia Pacific and 21.8% from Europe

Berkeley Lights Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

Berkeley Lights Online and Social Media Presence

Embed Graph

Berkeley Lights News and Updates

: Berkeley Lights stock bounces back after biotech, analysts dispute short seller’s ‘misleading’ report

Shares of Berkeley Lights Inc. bounced sharply Friday, after the cell biology company responded to a short seller's report that had helped fuel a brutal selloff to record lows, and as analysts also came to the company's defense.

Scott+Scott Attorneys at Law LLP Announces Investigation into Berkeley Lights, Inc. (BLI)

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, is investigating Berkeley Lights, Inc. (“Berkeley Lights” or the “Company”) (NASDAQ: BLI) on behalf of investors, concerning possible vio…

(BLI) Alert: Did You Lose Money on Your Berkeley Lights Investment? Contact Johnson Fistel Regarding Investigation

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by Berkeley Lights Inc. ("Berkeley Lights" or the "Company") (NASDAQ: BLI). 

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Berkeley Lights (BLI) Investors with Significant Loss to Contact Firm’s Attorneys Now, Firm Investigating Possible Securities Law Violations

SAN FRANCISCO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Berkeley Lights, Inc. (NASDAQ: BLI) investors with significant losses to submit your losses now.

Berkeley Lights Announces Appointment of Dr. Siddhartha Kadia to the Board of Directors

Kadia joins Board as an Independent Director who brings significant expertise in commercializing disruptive life science technologies Kadia joins Board as an Independent Director who brings significant expertise in commercializing disruptive life science technologies

Berkeley Lights to Participate in the Morgan Stanley Global Healthcare Conference

EMERYVILLE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.
Show more

Berkeley Lights Blogs

Maximize Functional Characterization of Your Precious T Cell Samples

Maximize Functional Characterization of Your Precious T Cell Samples crwadmin Thu, 04/09/2020 - 11:36 Summary In this webinar, we introduce you to new capabilities in the Cell Therapy Development Suite designed to empower you to get the most out of your T…

Application Note: Rapidly Discover and Select Potent Ligand/ Receptor Blocking Antibody Lead Candidates with Opto™ Plasma B Discovery

Application Note: Rapidly Discover and Select Potent Ligand/ Receptor Blocking Antibody Lead Candidates with Opto™ Plasma B Discovery crwadmin Wed, 04/01/2020 - 10:27 Summary Discover how you can maximize hit recovery and rapidly down-select blocking antibodies from plasma B c…

Application Note: Accessing Greater Antibody Sequence Diversity

Application Note: Accessing Greater Antibody Sequence Diversity crwadmin Tue, 03/31/2020 - 06:03 Summary See how you can discover >5,000 antigen-specific hits from a single plasma B cell sample and recover >650 unique BCR sequences in under 1 week. Se…

Rapid Discovery of Therapeutic Antibodies for SARS-CoV-2 Poster

Rapid Discovery of Therapeutic Antibodies for SARS-CoV-2 Poster crwadmin Tue, 03/31/2020 - 06:02 Summary Find out how B Cell Antibody Discovery on the Beacon system can be used to rapidly screen human B cell to discover antibodies against difficult targets such as viruses. …

TCRseq Well Plate Kit Datasheet

TCRseq Well Plate Kit Datasheet crwadmin Mon, 03/09/2020 - 06:33 Summary Review assay overview and results for recovering and amplifying T cell receptor alpha and beta chains. Section T Cell Functionality Analytics …

Culture Station Data Sheet

Culture Station Data Sheet crwadmin Mon, 01/27/2020 - 09:07 Summary Learn how you can increase scope, scale, and throughput of workflows run on the Beacon and Lightning platforms. Section Beacon Platform Lightning Platform…
Show more

Berkeley Lights Frequently Asked Questions

  • When was Berkeley Lights founded?

    Berkeley Lights was founded in 2011.

  • Who are Berkeley Lights key executives?

    Berkeley Lights's key executives are Andy Last, Kevin Chapman and Keith Breinlinger.

  • How many employees does Berkeley Lights have?

    Berkeley Lights has 208 employees.

  • What is Berkeley Lights revenue?

    Latest Berkeley Lights annual revenue is $56.7 m.

  • What is Berkeley Lights revenue per employee?

    Latest Berkeley Lights revenue per employee is $272.6 k.

  • Who are Berkeley Lights competitors?

    Competitors of Berkeley Lights include AbCellera Biologics, AXON Neuroscience and Mesoblast.

  • Where is Berkeley Lights headquarters?

    Berkeley Lights headquarters is located at 5858 Horton St #320, Emeryville.

  • Where are Berkeley Lights offices?

    Berkeley Lights has an office in Emeryville.

  • How many offices does Berkeley Lights have?

    Berkeley Lights has 2 offices.